English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
News
iCMLf CANDID data - The impact of COVID-19 for patients with CML
‘The iCMLf CANDID study gave confidence for physicians worldwide that their patients with well controlled CML were not at greater risk from COVID-19 than the general population and no changes to CML therapy specifically due to SARS-CoV-2 infection were required.’
(Professor Jorge Cortes)
December 2022 - Through 2020-2022 the real-world data from the iCMLf CML and COVID-19 registry has helped to answer key questions on the impact of COVID-19 for patients with CML and continues to explore the impact of specific factors on risks and outcomes, as the pandemic continues.
The recent poster presentation at the American Society of Hematology meeting - "A Risk Model for CML Patients with COVID-19:Importance of Molecular Response in the Context of Age, Comorbidities and Country Income has the conclusion that “based on our personalized risk model, the risk of COVID-19-related mortality was higher in patients not in MMR”. This continues to illustrate the risk factors for people with CML and inform them and their physicians.
Below we summarise the key data that have been presented at major meetings from this important registry.
Getting ready for ASH - Plan your CML Sessions
December 2022 - Only one week to go until the 64th Annual Meeting of the American Haematology Association that will take place in New Orleans from December 10-13, 2022. Participants will have the opportunity to attend the meeting in-person or virtually. Access to the virtual platform will begin on December 7, 2022.
For many of us this will be the first in person ASH since the pandemic began! To help you plan your CML meeting schedule we have compiled a list of CML related sessions for your convenience. There are three exciting opportunities to meet the iCMLf during and after the meeting:
- December 9th from 12.00 – 3.00 p.m. (CST at ASH): The iCMLf Forum will discuss future challenges of CML with presentations on treatment-free remission, disease persistence and resistance in CML
- December 12th from 6.00 – 8.00 p.m. (CST at ASH): Another sub-analysis of the iCMLf CML and COVID-19 CANDID data will be presented during a poster
- December 19th from 2.00 – 2.45 p.m. (Central European Time on Zoom): iCMLf Conversation with key clinical and biological highlights of ASH
We are looking forward to seeing you live in New Orleans or online!
If you like to get in touch with us during ASH, please email info@cml-foundation.org.
REMINDER: iCMLf Forum at ASH on Dec 9: First results of - Next big Challenges survey
November 2022 - What are the next big challenges in CML? What are the most promising new approaches? What brings us closer to a cure for CML? These are challenging questions and finding a cure for CML is complex. However, we want to address exactly this.
Do you want to help shape the discussion? Then join our speakers and panellists of renowned CML experts for the iCMLf Forum at ASH on December 9th. Details of the program can be found below. Please register ASAP by emailing arlene@cml-foundation.org as we do need to confirm numbers this week.
Even if you cannot attend the meeting in person you can still help. Participate in the survey to let us know the research questions you believe need to be answered to move us closer to a cure for CML.
Have a look at the first answers here...
Join us for CML Highlights of ASH on Dec 19th at 2 pm CET
November 2022 - During our last iCMLf Conversation for the year, in December we will present CML highlights from this year’s American Society of Hematology (ASH) Meeting.
Professor Ravi Bhatia (Birmingham) and Professor Michael Mauro (New York) will share the significant clinical and biological updates for CML that will be presented during the meeting.
If you will not be able to attend ASH, or would just like a recap of the CML highlights, this is an opportunity to get a first-hand, expert summary fresh from the conference.
Don’t miss out, join us for the live webinar on Zoom on Monday, December 19th at 2 pm Central European Time.
YOU ARE INVITED to discuss future directions of CML at the iCMLf Forum at ASH on Dec 9
November 2022 - We are looking forward to seeing you at the upcoming ASH Annual Meeting and welcoming you to our iCMLf Forum: ‘New next big challenges in CML?’
At this forum, we will take a look at future directions of CML. What are the next big challenges in CML? What are the most promising new approaches? What research questions need to be answered to help us to move closer to a cure for CML?
Our speakers and panellists of renowned experts in the field will share their perspectives and discuss key challenges in CML in the coming years. You are invited to join the discussion!
Numbers are limited. Please register ASAP by emailing arlene@cml-foundation.org
Read the iCMLf’s 2021-2022 Annual Report
We’re pleased to share the 2021-2022 iCMLf Annual Report. To begin, it’s a pleasure to start with a note from the Chairman and Chief Executive.
Dear Friends and Colleagues,
This year as we slowly work our way into a new normal after the peak of the pandemic, our efforts have solidified into two key areas:
- Harnessing our power through global research
- Raising the bar for CML best practice around the world
As we began our financial year in September 2021 the Omicron variant of SARS-CoV-2 had yet to arrive and we were still collecting cases for the iCMLf COVID-19 registry. Two hundred physicians from 58 countries submitted a total of 1,050 cases giving a truly global perspective of the impact of COVID-19 on people with CML. The four publications from this registry data have all shown that people with well-controlled CML have the same risk profile as that of the general population for outcomes of COVID-19. We are incredibly proud of the work and global collaboration that resulted from this registry in spite of the devastation that made it necessary.
